In addition to pushing cuts off until the beginning of 2027, the bill would update the data collection period used to establish the 2027 lab rates from 2019 to 2025.

The trial is being run by the Global Alzheimer's Platform Foundation in partnership with the UK Dementia Research Institute.

The Danaher subsidiary aims to meet clinician needs for flexibility with a range of test size options for its vast installed base.

The US Food and Drug Administration-approved comprehensive genomic profiling test will be reimbursed at a rate of $2,989.55 per test.